Ge Healthcare Technologies Inc Stock Price, News & Analysis

GE HealthCare (Nasdaq: GEHC) has announced its management team's participation in two upcoming investor conferences in September 2025. The company will present at the 2025 Wells Fargo Healthcare Conference on September 4 at 8:45 AM ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 9:15 AM ET.

Investors can access webcasts of both presentations through GE HealthCare's investor relations website at investor.gehealthcare.com/news-events/events.

GE HealthCare (Nasdaq: GEHC) reported strong Q2 2025 financial results with revenue growth of 3% year-over-year to $5.0 billion. The company achieved net income of $486 million with a margin of 9.7%, up from 8.9% in the prior year. Diluted EPS increased to $1.06 from $0.93.

The company raised its full-year 2025 guidance, projecting organic revenue growth of approximately 3% and adjusted EBIT margin of 15.2% to 15.4%. Free cash flow guidance was increased to at least $1.4 billion, up from the previous $1.2 billion target. Performance was driven by strong orders across all segments, particularly in the U.S. and EMEA regions, despite tariff impacts.

GE HealthCare (Nasdaq: GEHC) has announced the commercial launch of Definium™ Pace Select ET, an advanced floor-mounted digital X-ray system. The system addresses critical healthcare challenges, as X-ray exams represent 60% of all imaging studies while 80% of healthcare organizations face staff shortages.

The new system features AI-enabled automation to reduce manual tasks, streamline workflow, and ensure consistent image quality. Key innovations include the Helix™ Advanced Image Processing and Intelligent Workflow Suite, which automate positioning, protocol selection, and quality checks. The technology aims to increase efficiency in high-volume environments while maintaining affordability compared to more expensive overhead tube suspension systems.

GE HealthCare (Nasdaq: GEHC) has achieved a significant milestone by leading the FDA's AI-enabled medical device authorizations list for the fourth consecutive year, securing 100 authorizations to date. The company is advancing toward its goal of obtaining more than 200 authorizations by 2028.

The company's AI solutions span multiple areas including oncology, cardiology, and neurology, featuring innovative products such as AI-based Auto Positioning for CT and PET/CT devices, AIR™ Recon DL for MRI imaging with up to 50% faster scan times, and the LOGIQ™ Series ultrasound systems with AI-powered automation.

This achievement reflects GE HealthCare's strategic focus on R&D investment in AI-enabled medical devices, designed to enhance healthcare efficiency, improve diagnostic confidence, and address challenges such as care team shortages and rising costs.

GE HealthCare (Nasdaq: GEHC) has scheduled its second quarter 2025 financial results announcement for July 30, 2025, before market opening. The company's management team will host a conference call and webcast at 8:30 AM ET / 7:30 AM CT on the same day.

Investors can access the live webcast through the company's investor relations website. The earnings release, financial information, and webcast replay will be available at https://investor.gehealthcare.com/news-events/events.

GE HealthCare Technologies (Nasdaq: GEHC) has announced its quarterly dividend payment. The company's Board of Directors has declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025. The dividend will be paid on August 15, 2025 to shareholders of record as of July 25, 2025.

GE HealthCare (NASDAQ: GEHC) has received FDA approval for expanded indications of its Vizamyl PET imaging agent for beta-amyloid detection. The updated label now includes quantification capabilities for more objective amyloid measurements in the brain and removes previous limitations.

Key updates include the ability to monitor patient response to anti-amyloid therapies, predict development of dementia due to Alzheimer's disease, select patients for anti-amyloid therapies, and establish Alzheimer's disease diagnosis. The quantification feature enables calculation of amyloid load, improving diagnostic confidence and consistency among readers.

GE HealthCare showcases its advanced molecular imaging solutions at SNMMI 2025, highlighting its commitment to cardiac diagnostics. The company's flagship product, Flyrcado (flurpiridaz F 18) injection, represents a major breakthrough in nuclear cardiology as the first new PET myocardial perfusion tracer in nearly 20 years. The solution offers higher diagnostic efficacy compared to traditional SPECT MPI for coronary artery disease detection. Notably, Flyrcado has achieved significant coverage milestones, including CMS pass-through status and coverage by all Medicare Administrative Contractors, with over 50% of commercially insured beneficiaries now covered. GE HealthCare's portfolio also includes the Omni Legend PET/CT system, which has become their fastest-selling PET/CT platform, along with StarGuide and Aurora SPECT/CT systems for comprehensive cardiac imaging.

GE HealthCare (GEHC) unveils innovative advancements in theranostics and molecular imaging at SNMMI 2025, headlined by the introduction of LesionID Pro with automated zero-click pre-processing. This AI-powered software aims to streamline tumor analysis by eliminating manual segmentation requirements. The company showcases a comprehensive portfolio including the MINItrace Magni cyclotron, Omni Legend PET/CT system (reducing dose by up to 40%), StarGuide digital SPECT/CT, Aurora dual-head SPECT/CT, and Theranostics Pathway Manager Tile. These solutions support the growing field of theranostics, which combines diagnostic imaging and targeted therapies for personalized cancer treatment. The technology suite addresses the critical need for precision care solutions in oncology, where cancer causes over 10 million deaths globally each year.